Full-Time

Senior Medical Science Liaison

Oncology

Tango Therapeutics

Tango Therapeutics

51-200 employees

Develops synthetic-lethality cancer therapies

Compensation Overview

$157.6k - $236.4k/yr

Boston, MA, USA

Hybrid

Category
Biology & Biotech (1)
Required Skills
Google Cloud Platform
Requirements
  • 8 years of relevant experience with a bachelor's degree, 6 years with a master's degree, or 3 years with an advanced scientific or medical degree (e.g., PharmD, PhD, MD)
  • Candidates with advanced clinical degrees (e.g., Nurse Practitioner, Physician Assistant) and significant oncology Medical Science Liaison experience will also be considered
  • Experience in pancreatic ductal adenocarcinoma (PDAC), gastrointestinal malignancies, or non-small cell lung cancer (NSCLC) strongly preferred
  • Prior experience supporting clinical-stage or pre-launch oncology assets highly valued
  • Working knowledge of FDA, Office of Inspector General, International Council for Harmonisation, Good Clinical Practice, Pharmaceutical Research and Manufacturers of America Code, and applicable compliance standards
  • Proficiency in standard business and field tools (Customer Relationship Management systems, Microsoft Office, and virtual engagement platforms)
  • Field-based role in the Northeast (Boston/New York), with residence required within assigned territory
  • Approximately 50% domestic travel expected, with significant time spent with external scientific partners
Responsibilities
  • Build and sustain deep, credible relationships with priority investigators, key opinion leaders, and emerging scientific leaders in pancreatic cancer and non-small cell lung cancer
  • Conduct high-quality, fair-balanced scientific exchange in response to unsolicited requests, grounded in Tango’s biology, clinical data, and development strategy
  • Serve as a trusted scientific partner on disease biology, treatment paradigms, and evolving standards of care, particularly in high-unmet-need settings such as PDAC
  • Support Tango-sponsored clinical trials, with emphasis on site identification and activation, enrollment support and investigator engagement, and ongoing scientific dialogue to enhance trial conduct
  • Act as a Medical Affairs bridge between investigators and internal Clinical Development and Clinical Operations teams
  • Contribute field-based perspective to protocol feasibility, study design considerations, and operational execution
  • Capture and synthesize high-quality, hypothesis-driven insights from the field related to trial design and execution, competitive landscape, and future evidence needs
  • Translate insights into actionable feedback that informs Medical Strategy, Clinical Development, and future regulatory and commercialization readiness
  • Contribute to refinement of Tango’s core scientific narrative as programs mature and data evolve
  • Support planning and execution of advisory boards, investigator meetings, and other scientific forums
  • Represent Tango at major medical and scientific congresses relevant to PDAC, NSCLC, and precision oncology
  • Maintain up-to-date knowledge of relevant literature, competitive activity, and guideline evolution
  • Collaborate closely with Medical Affairs leadership, Medical Content, Clinical Development, Regulatory, and other cross-functional partners
  • Serve as a scientific resource to internal stakeholders
  • Uphold the highest standards of compliance, scientific integrity, and ethical engagement

Tango Therapeutics develops cancer medicines by leveraging synthetic lethality to selectively kill cancer cells while sparing healthy cells. Its approach focuses on creating drugs that exploit interactions between gene pairs, aiming for targeted therapies that spare normal tissue. The company advances its treatments through a strong R&D program and collaborates with larger pharmaceutical partners, such as Gilead Sciences, to co-develop therapies and accelerate commercialization. Revenue comes from these partnerships and funding rounds like its Series B. Tango differentiates itself with a dedicated emphasis on genetically targeted cancer therapies, a robust pipeline, and leadership that guides strategic collaborations. The company’s goal is to bring next-generation, genetically targeted immunotherapies to market, improving outcomes for cancer patients by precisely targeting tumor biology.

Company Size

51-200

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

2017

Simplify Jobs

Simplify's Take

What believers are saying

  • Vopimetostat's 25% ORR and 7.2-month mPFS in 2L pancreatic cancer support pivotal trial pathway toward potential accelerated approval.
  • Extended $379.8M cash runway into 2028 funds pivotal development and combination trials without immediate dilutive financing requirements.
  • Histology-agnostic cohort demonstrates 49% ORR and 9.1-month mPFS, validating vopimetostat's activity across multiple difficult-to-treat MTAP-deleted cancers.

What critics are saying

  • Pivotal pancreatic cancer trial failure would eliminate vopimetostat's lead asset and trigger existential equity collapse given asset concentration.
  • RAS(ON) combination trials with Revolution Medicines may fail to demonstrate synergy or acceptable safety, invalidating 2026 data catalyst.
  • Tango trades at 41.3x price-to-sales; any approval delay or revenue ramp miss triggers severe multiple compression and stock drawdown.

What makes Tango Therapeutics unique

  • Vopimetostat achieves 27% ORR across 16 MTAP-deleted cancer types with 6.4-month mPFS, best-in-class PRMT5 inhibitor profile.
  • Synthetic lethality platform targets homozygous MTAP deletion, a genetically defined population with limited competitive alternatives available.
  • Combination studies with Revolution Medicines' daraxonrasib and zoldonrasib show encouraging early efficacy, positioning vopimetostat as preferred RAS-targeted backbone.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Tango Therapeutics who can refer or advise you

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

4%
Yahoo Finance
Mar 30th, 2026
Tango Therapeutics exec sells $304K in stock after 36% single-day surge

Adam Crystal, President of R&D at Tango Therapeutics, sold 20,251 shares of common stock on 5 March 2026 for $304,000, according to an SEC Form 4 filing. The sale represented 15.24% of Crystal's direct ownership at the time. The transaction falls within Crystal's Rule 10b5-1 plan and aligns with his historical pattern of periodic sales since February 2025, though the sale size was above his recent median of 19,352 shares. No stock options were exercised in the transaction. Tango Therapeutics is a clinical-stage biotechnology company developing targeted oncology therapies. Its lead candidate, vopimetostat, targets cancers with specific genetic deletions. The company reported $62.38 million in trailing twelve-month revenue and a net loss of $101.59 million.

Yahoo Finance
Mar 6th, 2026
Tango Therapeutics hits all-time high of $16.97 as Stifel reaffirms buy rating

Tango Therapeutics shares surged 36.28% to $16.83, reaching an all-time high of $16.97 during intraday trading, following a bullish note from Stifel. The investment firm reaffirmed its "buy" rating and $15 price target, 21% above the previous day's close. The biotech company narrowed its 2024 net loss by 22% to $101.59 million, whilst total revenues jumped 48.3% to $62.38 million year-on-year. However, fourth-quarter net loss widened 26% to $38.7 million, with no revenues during the period. Tango Therapeutics plans to initiate clinical trials this year testing drug candidate vopimetostat in combination with multiple inhibitors for pancreatic cancer treatment. The company recently signed a collaboration agreement with Erasca to study vopimetostat combined with ERAS-0015.

Sahm Capital
Feb 3rd, 2026
Tango Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Tango Therapeutics to participate in the Guggenheim Emerging Outlook: Biotech Summit 2026. Tango Therapeutics, Inc. +0.48% Pre BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) - Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Malte Peters, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026 at 2:00 PM EST. The live webcast will be available under the "Events & Presentations" tab on the "Investors" page of the Company's website on the day of the event. A replay of the webcast will be archived on the Company's website for 90 days following the presentation. About Tango Therapeutics Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit www.tangotx.com. Investors and Media: Elizabeth Hickin [email protected] [email protected] This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.

Castle Placement
Dec 4th, 2025
Top 10 Oncology Capital Raises and Investors in the U.S. - October 16th - November 15th, 2025

Top 10 Oncology capital raises and investors in the U.S. - october 16th - november 15th, 2025. Several interesting transactions closed in the Oncology sector over the past two weeks. If you would like more info on these deals or would like to discuss the capital raising market for your company, please contact me. * * Neuphoria Therapeutics, that develops therapies that addresses the complex needs of individuals affected by neuropsychiatric disorders, received $3.28 million of development capital from Lynx1 Capital Management through a private placement. * Tango Therapeutics, biotechnology company that discovers novel drug targets and delivers the next generation of precision medicine for the treatment of cancer, received $197.06 million of development capital from Nextech Invest, Boxer Capital, The Invus Group, TCG Crossover Management, Farallon Capital Management, Logos Capital, Woodline Partners, Balyasny Asset Management, Adage Capital Management and Nantahala Capital Management through a private placement.

Simply Wall St
Oct 27th, 2025
Tango Therapeutics: $210M Raise, Valuation Concerns

Tango Therapeutics (TNGX) announced promising Phase 1/2 data for vopimetostat in MTAP-deleted cancers and raised $210 million to advance its pipeline. Despite a 139% year-to-date share price increase, shares trade at a 30% discount to analyst targets. The current price-to-sales ratio of 41.3x is considered overvalued compared to industry norms. While recent achievements boost confidence, unprofitability and reliance on future breakthroughs pose risks.